Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 8/20 | 0.34 |
| ▸ | NMT2 | O60551 | 7/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18872895 | 0.91 | MEN1 (0.39) | MEN1KMT2AKDM4CCA12CA1 | |
| SCHEMBL13219107 | 0.84 | MEN1 (0.36) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL9308239 | 0.79 | MEN1 (0.49) | MEN1KMT2AKDM4C | |
| SCHEMBL9705177 | 0.79 | MEN1 (0.54) | MEN1KMT2AKDM4C | |
| SCHEMBL9306096 | 0.77 | MEN1 (0.47) | MEN1KMT2AKDM4C | |
| SCHEMBL9705239 | 0.77 | MEN1 (0.49) | MEN1KMT2AKDM4C | |
| SCHEMBL26666204 | 0.76 | MEN1 (0.50) | MEN1KMT2AKDM4C | |
| SCHEMBL15028143 | 0.76 | MEN1 (0.50) | MEN1KMT2AKDM4C | |
| SCHEMBL2966296 | 0.75 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL6947738 | 0.74 | MEN1 (0.50) | MEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768708-B1 | N4 CHELATOR CONJUGATES | GE HEALTHCARE LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-7767796-B2 | N4 chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-7767796-B2 | N4 chelator conjugates | GE HEALTHCARE LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20080279765-A1 | Novel Imaging Agents for Fibrosis | CHETTIBI SALAH | 2008-11-13 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080131368-A1 | N4 Chelator Conjugates | GE HEALTHCARE LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279765-A1 | Novel Imaging Agents for Fibrosis | M6PR, IGF2R, MPI | MEN1 693/4885KMT2A 3040/4885NMT1 1271/4885 |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | MEN1 559/4885KMT2A 4035/4885NMT1 1644/4885 |
| US-20080131368-A1 | N4 Chelator Conjugates | TTK, PIGK, HUNK | MEN1 44/4885KMT2A 1001/4885NMT1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.